I believe that what we should realize when we speak of the Royalty Preferred and their payments is that the original setup of Zenith was done in the expectation that Assure would be successful and that a negotiation would have a deal with a Pharma which would be willing to pay a lot if the drug was successful commercially and little if it was not.

I believe that it was set up with a smaller payment at the start and big payments as royalties. That would mean that if it was successful a big part of a big payment would occur as royalties and if it was not commercially successful then from the viwpoint of Pharma; what the heck a relatively small amount had been paid as a purchase of RVX.

We are now facing the fact that assure failed since Lipitor destroys the benefit of RVX 208. We have seen that with Crestor it succeeds very well and we are going ahead and running a business which will licence out RVX 208 and do a phase III and not sell the company. Of course a future sale of RVX could always occur further down the road as a sale of a successful company for a bigger upfront price than was previously envisioned; but that is not what is being talked about here.

As such with RVX an operating company the shareholders of RVX 208 will collect revenues and pass a revised royalty on to Zenith based on a reasonable 3rd party negotiated deal and not on the basis of a deferred payment for sale of RVX the company.